Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review.
Calcipotriol/betamethasone dipropionate
Cream
PAD Technology
Psoriasis
Satisfaction
Topicals
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
05
07
2023
accepted:
02
08
2023
medline:
23
9
2023
pubmed:
23
9
2023
entrez:
23
9
2023
Statut:
ppublish
Résumé
Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line choice in topical psoriasis treatment. A CAL/BDP cream based on polyaphron dispersion (PAD) Technology has emerged as a novel formulation for a more convenient topical treatment of psoriasis. This article aims to summarize the most relevant published evidence about CAL/BDP PAD-cream and its underlying PAD Technology. The PAD Technology enables CAL and BDP stability in an aqueous cream through a multimolecular shell structure, as well as it increases the penetration of both active ingredients into the epidermis and dermis. This technology also demonstrated to increase the cosmetic acceptability and to provide the desirable sensory properties for a topical psoriasis treatment. Two phase III clinical trials have been conducted so far with CAL/BDP PAD-cream. Findings from both trials revealed high efficacy with a fast onset of action, a favourable safety and tolerability profile and convenience for CAL/BDP PAD-cream compared to CAL/BDP gel. In the trial including patients with psoriasis affecting the scalp (MC2-01-C7), results support the use of CAL/BDP PAD-cream in scalp psoriasis. An anchored matching-adjusted indirect comparison (MAIC) was conducted to compare CAL/BDP PAD-cream and CAL/BDP foam, as both products had been previously compared to CAL/BDP gel. CAL/BDP PAD-cream and CAL/BDP foam showed equivalent efficacy and quality of life at their recommended treatment duration, whereas greater treatment satisfaction for CAL/BDP PAD-cream was found after one week of treatment. Overall, the high patient acceptability and treatment satisfaction observed with CAL/BDP PAD-cream in clinical trials may lead to improved adherence and hence higher efficacy in clinical practice.
Identifiants
pubmed: 37740858
doi: 10.1007/s13555-023-01003-0
pii: 10.1007/s13555-023-01003-0
pmc: PMC10539254
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2153-2169Informations de copyright
© 2023. The Author(s).
Références
J Dermatolog Treat. 2022 Dec;33(8):3191-3198
pubmed: 36036596
J Drugs Dermatol. 2022 Mar 1;21(3):242-248
pubmed: 35254765
Actas Dermosifiliogr. 2013 Jul-Aug;104(6):488-96
pubmed: 23395400
J Drugs Dermatol. 2023 Mar 1;22(3):271-273
pubmed: 36877880
J Dermatolog Treat. 2021 Aug;32(5):478-483
pubmed: 31610687
J Eur Acad Dermatol Venereol. 2023 Jan;37 Suppl 1:9-13
pubmed: 36546463
Dermatol Ther. 2022 Dec;35(12):e15931
pubmed: 36226669
Dermatol Ther (Heidelb). 2017 Sep;7(3):265-279
pubmed: 28785924
Drugs Context. 2023 Mar 20;12:
pubmed: 36968458
Dermatol Ther (Heidelb). 2023 Aug;13(8):1763-1771
pubmed: 37351830
Am J Clin Dermatol. 2022 Jan;23(1):13-24
pubmed: 34705167
J Drugs Dermatol. 2021 Apr 1;20(4):420-425
pubmed: 33852251
J Eur Acad Dermatol Venereol. 2023 Jan;37 Suppl 1:14-19
pubmed: 36546465
J Dermatolog Treat. 2019 Nov;30(7):659-663
pubmed: 30470146
J Eur Acad Dermatol Venereol. 2023 Jan;37 Suppl 1:3-8
pubmed: 36546464
Cutis. 2022 Aug;110(2 Suppl):8-14
pubmed: 36219602
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):228-236
pubmed: 34628687
Dermatol Ther (Heidelb). 2022 Oct;12(10):2217-2231
pubmed: 36050567
Indian Dermatol Online J. 2017 Jul-Aug;8(4):235-245
pubmed: 28761838
Expert Rev Clin Immunol. 2020 Jun;16(6):599-620
pubmed: 32476507
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284
pubmed: 28419600